3.6  0.22 (6.51%)		10-15 16:00
Open: 3.39 High: 3.665 Volume: 1,558,095		Pre. Close: 3.38 Low: 3.38 Market Cap: 622(M)

Short term
Mid term
Targets	6-month :	4.29	1-year :	4.54
Resists	First :	3.67	Second :	3.89
Pivot price	3.47
Supports	First :	3.33	Second :	2.77
MAs	MA(5) :	3.43	MA(20) :	3.48
	MA(100) :	2.83	MA(250) :	2.97
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	38.6	D(3) :	24.5
RSI	RSI(14): 60.6
52-week	High :	4.29	Low :	1.88

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ SVRA ] has closed below upper band by 2.2%. Bollinger Bands are 59.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.67 - 3.69	3.69 - 3.71
Low:	3.33 - 3.36	3.36 - 3.38
Close:	3.56 - 3.61	3.61 - 3.64

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Wed, 15 Oct 2025
SVRA DEADLINE ALERT: Savara Inc. Investors Encouraged to - GlobeNewswire

Wed, 15 Oct 2025
Savara Inc. (SVRA) Shareholders Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Tue, 14 Oct 2025
Deadline Alert: Savara Inc. (SVRA) Shareholders Who Lost - GlobeNewswire

Mon, 13 Oct 2025
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Sun, 12 Oct 2025
SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - FinancialContent

Fri, 10 Oct 2025
SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	173 (M)
Shares Float	91 (M)
Held by Insiders	5.3 (%)
Held by Institutions	97.7 (%)
Shares Short	13,770 (K)
Shares Short P.Month	15,680 (K)

EPS	-0.51
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.56
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-48.1 %
Return on Equity (ttm)	-99.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.45
Sales Per Share	0
EBITDA (p.s.)	-0.68
Qtrly Earnings Growth	0 %
Operating Cash Flow	-99 (M)
Levered Free Cash Flow	-57 (M)

PE Ratio	-7.06
PEG Ratio	0
Price to Book value	6.31
Price to Sales	0
Price to Cash Flow	-6.26

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.